@inbook{c5984139526c4dabb25c872e9dfd94b2,
title = "Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)",
abstract = "Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwithstanding various conventional antidepressant treatment options, a large portion of depressed people (ca. 30%) fails to respond to first-line treatment, resulting in treatment-resistant depression (TRD). Although non-response to multiple antidepressant interventions is a common outcome, a consensus definition of TRD is not yet available. In practice, TRD is applied when two or more successive treatments with different antidepressants are not working. The last decade{\textquoteright}s intense research into new medicines for TRD has led to two developments, using typical or serotonergic (psilocybin, ayahuasca) and atypical (glutamatergic) psychedelics (ketamine, esketamine). Both approaches, although via different entrance mechanism, exhibit a fast onset but also long-lasting antidepressant effect far beyond the biological presence of the drug in the body, strongly indicating that downstream mechanisms activated by signaling cascades in the brain are involved. The present chapter describes the clinical development of psilocybin and esketamine for TRD and discusses the problems involved in the use of a proper placebo because of the psychotomimetic (psilocybin) or dissociative (ketamine) effects that interfere with performing “blind” studies. Nevertheless, intranasal esketamine was developed and approved for TRD, whereas psilocybin has shown positive results. Adverse effects and tolerability of both drugs in the dose ranges used are generally acceptable. The emergence of anti-TRD medicines for treatment of a very severe disease is a breakthrough in psychiatry.",
keywords = "5-HT receptor agonist, Antidepressants, Ayahuasca, Depression, Dissociation, Efficacy, Enantiomers, Esketamine, Ketamine, NMDA receptor antagonist, Psilocybin, Psychedelic, Psychotomimetic, Safety, Tolerability, Treatment-resistant depression",
author = "Berend Olivier and Olivier, {Jocelien D.A.}",
note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2024.",
year = "2024",
month = sep,
day = "13",
doi = "10.1007/978-981-97-4402-2_3",
language = "English",
isbn = "978-981-97-4401-5",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer",
pages = "49--66",
booktitle = "Recent Advances and Challenges in the Treatment of Major Depressive Disorder",
address = "Germany",
}